

HealthBIO

How does Bayer Drive Changes in Healthcare?

Dr. Miriam Holstein CEO Bayer Nordic

05 September 2018 Turku







Science For A Better Life

Pharmaceuticals



Prescription drugs

Consumer Health



- **# Over-the-counter medicines**
- // Dietary supplements
- // Dermatology products
- Foot care and sunscreen

Crop Science



- Innovative crop protection and seeds
- // Animal Health



Key Data Bayer Group







Investment in research & development

€4.5 bill



Countries

79



Opportunities & Challenges

Growing Population



Aging Population

2billion >60 year-olds by 2050

Cost Containment

Stricter Regulatory Conditions

Changing Competitive Landscape

Pharma R&D Productivity Challenge

Digitalization

Advanced Biotechnologies

Collaboration

Innovative Environment



Internal Innovation Through R&D and Product Supply



Supply Center and Chemical & Pharmaceutical Development (Turku)

Unique Production Site High Strategic Importance

Clinical Studies (Espoo)

4th largest> 40> 30Clinical Development HubCountriesOngoing Global Studies

Core Business Areas

Cardiology, Oncology, Hemophilia, Ophthalmology & Women's Health



External Innovation Through Broad Open Innovation Networks



Grants4Apps and other global G4 Innovation Programs





External Innovation Through A Deeply Integrated Ecoystem

Data Analytics



Bio, Pharma & Medical Technology



Prevention




Test Beds & Accelerators



Bio Banks

- · Finnish Genome Center
- Cancer Center Finland (FICAN)
- Neuro Center Finland
- Finnish Biobank (FINBB)
- Suomen Terveystalon Biopankki



Multinomics & Research



Technology & Enablers



Remote Solutions



Health Services



Diagnostics & Imaging



Education & Research





Innovation calls for

Perseverance

"A noble purpose stimulates innovation and encourages perseverance."

Dr. Gary Hamel





Reach out to us!

Arto Pakkalin (arto.pakkalin@bayer.com) Bayer Nordic, Innovation & Partnerships

HealthBIO05 September 2018
Turku

